Loading
TNG260 is a small-molecule inhibitor from Tango Therapeutics, Inc., in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.
TNG260 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Tango Therapeutics, Inc., in non-small-cell lung cancer, small-cell lung cancer. Described in the registry record as a corest inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
Described in the registry record as a corest inhibitor; the trial entries below carry the sponsor's wording.
1.TNG260 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"TNG260" OR ABSTRACT:"TNG260") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TNG260, not a curated reading list.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tags pipeline, registry-only.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tags pipeline, registry-only.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tags pipeline, registry-only.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tags pipeline, registry-only.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tags pipeline, registry-only.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tags pipeline, registry-only.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tags pipeline, registry-only.
Shares Non-small-cell lung cancer and the tags pipeline, registry-only.